Trial Profile
Clinical study of hydrochloride anlotinib combined with concurrent radiochemotherapy for locally advanced (stage IIB-IVA) cervical squamous cell carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 03 Dec 2020
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; Catequentinib (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 03 Dec 2020 New trial record